The Effect of Cumulative Length of Hospital Stay on the Antifungal Resistance of Candida Strains Isolated from Critically Ill Surgical Patients

Mycopathologia

Volumn 171, Issue 2, 2011, Pages 85-91

  Kourkoumpetis, Themistoklis K ^a   Velmahos, George C ^a   Ziakas, Panayiotis D ^b   Tampakakis, Emmanouil ^a   Manolakaki, Dimitra ^a   Coleman, Jeffrey J ^a   Mylonakis, Eleftherios ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Candida; Candidiasis; Emergency surgery; Fluconazole; Resistance; Risk factor

Indexed keywords

CANDIDA;

EID: 78651396843     PISSN: 0301486X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11046-010-9369-3     Document Type: Article

References (42)

1. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev. 2007; 20(1): 133-63. doi: 20/1/133[pii]10. 1128/CMR. 00029-06.
2. Pfaller MA, Diekema DJ, Gibbs DL, Newell VA, Meis JF, Gould IM, et al. Results from the artemis disk global antifungal surveillance study, 1997 to 2005: an 8. 5-year analysis of susceptibilities of Candida species and other yeast species to fluconazole and voriconazole determined by clsi standardized disk diffusion testing. J Clin Microbiol. 2007; 45(6): 1735-45. doi: JCM. 00409-07[pii]10. 1128/JCM. 00409-07.
3. Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. Lancet Infect Dis. 2003; 3(11): 685-702. doi: S1473309903008016[pii].
4. Manolakaki D, Velmahos GC, Kourkoumpetis T, Chang Y, Alam H, De Moya M et al. Candida infection and colonization among trauma patients. Virulence (in press). 2010.
5. Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in us hospitals: analysis of 24, 179 cases from a prospective nationwide surveillance study. Clin Infect Dis. 2004; 39(3): 309-17. doi: 10. 1086/421946CID32752[pii].
6. Pfaller MA, Jones RN, Messer SA, Edmond MB, Wenzel RP. National surveillance of nosocomial blood stream infection due to species of Candida other than Candida albicans: frequency of occurrence and antifungal susceptibility in the scope program. Scope participant group. Surveillance and control of pathogens of epidemiologic. Diagn Microbiol Infect Dis. 1998; 30(2): 121-9. doi: S0732889397001922[pii].
7. Marchetti O, Bille J, Fluckiger U, Eggimann P, Ruef C, Garbino J, et al. Epidemiology of candidemia in swiss tertiary care hospitals: secular trends, 1991-2000. Clin Infect Dis. 2004; 38(3): 311-20. doi: CID31584[pii]10. 1086/380637.
8. Aperis G, Mylonakis E. Newer triazole antifungal agents: pharmacology, spectrum, clinical efficacy and limitations. Expert Opin Investig Drugs. 2006; 15(6): 579-602. doi: 10. 1517/13543784. 15. 6. 579.
9. Horn DL, Neofytos D, Anaissie EJ, Fishman JA, Steinbach WJ, Olyaei AJ et al. Epidemiology and outcomes of candidemia in 2019 patients: data from the prospective antifungal therapy alliance registry. Clin Infect Dis. 2009. doi: 10. 1086/599039.
10. Nowakowska D, Gaj Z, Sobala W, Wilczynski J. Evaluation of susceptibility to antifungal agents of fungal strains isolated from pregnant women with diabetes and healthy pregnant women. Ginekol Pol. 2009; 80(4): 274-9.
11. Lee I, Fishman NO, Zaoutis TE, Morales KH, Weiner MG, Synnestvedt M, et al. Risk factors for fluconazole-resistant Candida glabrata bloodstream infections. Arch Intern Med. 2009; 169(4): 379-83. doi: 169/4/379[pii]10. 1001/archinte. 169. 4. 379.
12. Playford EG, Marriott D, Nguyen Q, Chen S, Ellis D, Slavin M, et al. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit Care Med. 2008; 36(7): 2034-9. doi: 10. 1097/CCM. 0b013e3181760f42.
13. Chow JK, Golan Y, Ruthazer R, Karchmer AW, Carmeli Y, Lichtenberg D, et al. Factors associated with candidemia caused by non-albicans Candida species versus Candida albicans in the intensive care unit. Clin Infect Dis. 2008; 46(8): 1206-13. doi: 10. 1086/529435.
14. Dimopoulos G, Ntziora F, Rachiotis G, Armaganidis A, Falagas ME. Candida albicans versus non-albicans intensive care unit-acquired bloodstream infections: differences in risk factors and outcome. Anesth Analg. 2008; 106(2): 523-9, table of contents. doi: 106/2/523 [pii]10. 1213/ane. 0b013e3181607262.
15. Hachem R, Hanna H, Kontoyiannis D, Jiang Y, Raad I. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer. 2008; 112(11): 2493-9. doi: 10. 1002/cncr. 23466.
16. Lin MY, Carmeli Y, Zumsteg J, Flores EL, Tolentino J, Sreeramoju P, et al. Prior antimicrobial therapy and risk for hospital-acquired Candida glabrata and Candida krusei fungemia: a case-case-control study. Antimicrob Agents Chemother. 2005; 49(11): 4555-60. doi: 49/11/4555[pii]10. 1128/AAC. 49. 11. 4555-4560. 2005.
17. Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S. Clinical factors associated with fluconazole resistance and short-term survival in patients with Candida bloodstream infection. Eur J Clin Microbiol Infect Dis. 2004; 23(5): 380-8. doi: 10. 1007/s10096-004-1128-2.
18. Kovacicova G, Spanik S, Kunova A, Trupl J, Sabo A, Koren P, et al. Prospective study of fungaemia in a single cancer institution over a 10-y period: aetiology, risk factors, consumption of antifungals and outcome in 140 patients. Scand J Infect Dis. 2001; 33(5): 367-74.
19. Vazquez JA, Peng G, Sobel JD, Steele-Moore L, Schuman P, Holloway W, et al. Evolution of antifungal susceptibility among Candida species isolates recovered from human immunodeficiency virus-infected women receiving fluconazole prophylaxis. Clin Infect Dis. 2001; 33(7): 1069-75. doi: CID001536[pii]10. 1086/322641.
20. Masia Canuto M, Gutierrez Rodero F, Ortiz de la Tabla Ducasse V, Hernandez Aguado I, Martin Gonzalez C, Sanchez Sevillano A, et al. Determinants for the development of oropharyngeal colonization or infection by fluconazole-resistant Candida strains in HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2000; 19(8): 593-601.
21. Harris AD, Castro J, Sheppard DC, Carmeli Y, Samore MH. Risk factors for nosocomial candiduria due to Candida glabrata and Candida albicans. Clin Infect Dis. 1999; 29(4): 926-8. doi: 10. 1086/520460.
22. Chryssanthou E, Cherif H, Petrini B, Kalin M, Bjorkholm M. Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies. Scand J Infect Dis. 2004; 36(11-12): 855-9. doi: P5KUY78Y80VPUB2W[pii]10. 1080/00365540410021108.
23. Kourkoumpetis T, Manolakaki D, Velmahos G, Chang Y, Alam H, De Moya M et al. Candida infection and colonization among non-trauma emergency surgery patients. Virulence (in press). 2010.
24. Velmahos GC, Jurkovich GJ. The concept of acute care surgery: a vision for the not-so-distant future. Surgery. 2007; 141(3): 288-90. doi: S0039-6060(07)00058-X[pii]10. 1016/j. surg. 2006. 12. 017.
25. Borst A, Raimer MT, Warnock DW, Morrison CJ, Arthington-Skaggs BA. Rapid acquisition of stable azole resistance by Candida glabrata isolates obtained before the clinical introduction of fluconazole. Antimicrob Agents Chemother. 2005; 49(2): 783-7. doi: 49/2/783[pii]10. 1128/AAC. 49. 2. 783-787. 2005.
26. Hota B. Contamination, disinfection, and cross-colonization: are hospital surfaces reservoirs for nosocomial infection? Clin Infect Dis. 2004; 39(8): 1182-9. doi: CID33640[pii]10. 1086/424667.
27. Holland ML, Kunz LJ. Evaluation of molybdate agar as a selective, differential medium for yeasts. J Bacteriol. 1961; 81: 869-74.
28. Freydiere AM, Guinet R, Boiron P. Yeast identification in the clinical microbiology laboratory: phenotypical methods. Med Mycol. 2001; 39(1): 9-33.
29. National Committee for Clinical Laboratory Standards. Method for antifungal disk diffusion susceptibility testing of yeasts. Approved standard m44-a. National committee for clinical laboratory standards, wayne, pa. 2004.
30. Reference method for broth dilution antifungal susceptibility testing of yeasts: approved standard. Wayne PNCoCLS, 1997. (NCCLS document no. M27-A.).
31. Rex JH, Pfaller MA, Galgiani JN, Bartlett MS, Espinel-Ingroff A, Ghannoum MA, et al. Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on antifungal susceptibility testing of the national committee for clinical laboratory standards. Clin Infect Dis. 1997; 24(2): 235-47.
32. Pfaller MA, Diekema DJ, Sheehan DJ. Interpretive breakpoints for fluconazole and Candida revisited: a blueprint for the future of antifungal susceptibility testing. Clin Microbiol Rev. 2006; 19(2): 435-47. doi: 19/2/435[pii]10. 1128/CMR. 19. 2. 435-447. 2006.
33. Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob Agents Chemother. 2005; 49(9): 3640-5. doi: 49/9/3640[pii]10. 1128/AAC. 49. 9. 3640-3645. 2005.
34. Labelle AJ, Micek ST, Roubinian N, Kollef MH. Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med. 2008; 36(11): 2967-72. doi: 10. 1097/CCM. 0b013e31818b3477.
35. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the infectious diseases society of America. Clin Infect Dis. 2009; 48(5): 503-35. doi: 10. 1086/59675710. 1086/596757[pii].
36. Odds FC. Long-term laboratory preservation of pathogenic yeasts in water. J Med Vet Mycol. 1991; 29(6): 413-5.
37. Traore O, Springthorpe VS, Sattar SA. A quantitative study of the survival of two species of Candida on porous and non-porous environmental surfaces and hands. J Appl Microbiol. 2002; 92(3): 549-55. doi: 1560[pii].
38. Barchiesi F, Calabrese D, Sanglard D, Falconi Di Francesco L, Caselli F, Giannini D, et al. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750. Antimicrob Agents Chemother. 2000; 44(6): 1578-84.
39. Pinto e Silva AT, Costa-de-Oliveira S, Silva-Dias A, Pina-Vaz C, Rodrigues AG. Dynamics of in vitro acquisition of resistance by Candida parapsilosis to different azoles. FEMS Yeast Res. 2009; 9(4): 626-33. doi: FYR508[pii]10. 1111/j. 1567-1364. 2009. 00508. x.
40. Marr KA, Lyons CN, Rustad TR, Bowden RA, White TC. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mrna levels of CDR. Antimicrob Agents Chemother. 1998; 42(10): 2584-9.
41. Calvet HM, Yeaman MR, Filler SG. Reversible fluconazole resistance in Candida albicans: a potential in vitro model. Antimicrob Agents Chemother. 1997; 41(3): 535-9.
42. Marr KA, Lyons CN, Ha K, Rustad TR, White TC. Inducible azole resistance associated with a heterogeneous phenotype in Candida albicans. Antimicrob Agents Chemother. 2001; 45(1): 52-9. doi: 10. 1128/AAC. 45. 1. 52-59. 2001.